Sleeping Beauty enables efficient gene transfer in haematopoietic stem cells of humans
Gene therapy of haematopoietic stem cells aims at a life-long therapeutically effective correction of these cells in humans with particular genetic disorders. This therapeutic approach has proved to be effective in clinical trials while the risk of leukaemia development as a side-effect of the therapy must be kept as low as possible. In an international research network, researchers of the Paul-Ehrlich-Institut have developed a method using "jumping genes" (transposons) to transfer genes efficiently and to anchor them in the genome of the modified cells.
The road to new therapy options using TNF blockers: The winners of the Paul Ehrlich- and Ludwig Darmstaedter-Award 2018 present their research results at the Paul-Ehrlich-Institut
Professor David Wallach and Professor Anthony Cerami, this year's winners of the Paul Ehrlich- and Ludwig Darmstaedter Award, continued the tradition and accepted the annual invitation to the Paul-Ehrlich-Institut (PEI) to present their research work prior to the official award ceremony in a scientific colloquium. They performed research on a messenger substance, the so-called tumor necrosis factor (TNF) and its cell receptors.
EMA recommends immediate recall of the multiple sclerosis medicine Zinbryta (Daclizumab)
The Paul-Ehrlich-Institut (PEI), Federal Institute for Vaccines and Biomedicines has received reports on serious cases of autoimmune reactions in patients with multiple sclerosis treated with the antibody Daclizumab (see note on the PEI website from 2 March 2018). Upon this report, the marketing authorisation holder notified the authorities that it would renounce the marketing authorisation and initiate a recall at its own discretion. The European Medicines Agency (EMA) has now recommended a suspension and a recall of Zinbryta (Daclizumab)